Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
SEC, Cassava and Alzheimer's
Cassava Sciences settles SEC charges of ‘misleading’ Alzheimer’s trial claims
Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S. securities regulators, who had charged the pharma company and two former executives for “misleading claims” about an Alzheimer’s clinical trial.
SEC brings securities fraud charges against Cassava Sciences
The SEC announced last week that it had filed a complaint against Cassava Sciences, Inc., a “pharmaceutical company with one primary drug
SEC charges Cassava over 'misleading' Alzheimer's claims
The Securities & Exchange Commission (SEC) has accused Cassava's founder and former chief executive Remi Barbier and former head of neuroscience Dr Lindsay Burns of misleading investors by announcing that the company’s small-molecule therapeutic simufilam significantly improved patient cognition in the phase 2b study.
Cassava Sciences and former execs, facing SEC charges for misleading claims, agree to fines
Cassava and former executives were charged Thursday by the SEC with making misleading claims in 2020 about trials for the Alzheimer's drug simufilam, and agreed to pay fines.
SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty
Alzheimer’s drug developer Cassava Sciences Inc (NASDAQ:SAVA), its founder Remi Barbier, and former Senior VP of Neuroscience Lindsay Burns have agreed to pay over $40 million to resolve SEC charges over misleading statements related to a Phase 2 trial of the company’s controversial Alzheimer’s drug,
Cassava Sciences shares fall after SEC charges for misleading Alzheimer's drug trial claims
Shares of Cassava Sciences fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission charged the biopharmaceutical company and two former executives for misleading claims about the results of Alzheimer's clinical trials.
Cassava Sciences settles with SEC for $40M over skewed Alzheimer’s drug data
A former Alzheimer's researcher manipulated the results of a Cassava Sciences drug, with the pharmaceutical company and its former chief executive reaching a $40 million settlement with the Securities and Exchange Commission over allegedly misleading the public.
Cassava, former execs ink SEC deal to resolve allegations around misleading Alzheimer's data drop
Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made m | Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made misleading statements about phase 2b data on its Alzheimer’s disease drug candidate.
SEC Charges Cassava Sciences, Former Executives for Misleading Claims in Alzheimer's Trial
Cassava Sciences and two former executives will pay more than $40 million to settle charges related to misleading statements made about a clinical trial for the company's purported therapeutic treatment of Alzheimer's disease,
4d
on MSN
Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's Claims
Key Takeaways Cassava Sciences and two former executives agreed to pay more than $40 million in a settlement with the SEC.The ...
5d
Cassava Sciences Resolves SEC Investigation
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company ...
4d
Why Cassava Sciences Stock Dived by Almost 11% Today
Before market open, Cassava announced that it has reached agreement with the U.S. Securities and Exchange Commission (SEC) to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback